Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Worldwide, also known as Worldwide Clinical Trials, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in the United States. Founded in 1999, the company has established itself as a leader in providing comprehensive clinical trial services, with a strong operational presence across North America, Europe, and Asia.
Specialising in the development and manufacturing of innovative pharmaceutical products, Worldwide is recognised for its commitment to quality and efficiency. The company’s unique approach combines advanced technology with a deep understanding of regulatory requirements, ensuring that its offerings meet the highest industry standards.
With a focus on enhancing patient outcomes, Worldwide has achieved significant milestones, including numerous successful drug approvals and partnerships with leading pharmaceutical companies. Its reputation for excellence positions Worldwide as a trusted partner in the global pharmaceutical landscape.
-19 vs industry average
Worldwide’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Worldwide yet.
Worldwide, a US-headquartered pharmaceutical preparation manufacturing company, does not publicly report its carbon emissions data. However, the company has demonstrated a commitment to climate action by committing to the Science Based Targets initiative (SBTi). This commitment, originating from Worldwide Clinical Trials Holdings, Inc., signifies their intention to set emissions reduction targets in line with climate science. Additionally, Worldwide has committed to achieving net-zero emissions, with this commitment also cascaded from Worldwide Clinical Trials Holdings, Inc.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more